Literature DB >> 20937457

Epidemiology and management of hepatocellular carcinoma.

Ju Dong Yang1, Lewis R Roberts.   

Abstract

Hepatocellular carcinoma (HCC) is a major world health problem because of the high incidence and case fatality rate. In most patients, the diagnosis of HCC is made at an advanced stage, which limits the application of curative treatments. Most HCCs develop in patients with underlying chronic liver disease. Chronic viral hepatitis B and C are the major causes of liver cirrhosis and HCC. Recent improvements in treatment of viral hepatitis and in methods for surveillance and therapy for HCC have contributed to better survival of patients with HCC. This article reviews the epidemiology, cause, prevention, clinical manifestations, surveillance, diagnosis, and treatment approach for HCC.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20937457      PMCID: PMC3949429          DOI: 10.1016/j.idc.2010.07.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  126 in total

Review 1.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

2.  A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.

Authors:  Francis Y Yao; Ryutaro Hirose; Jeanne M LaBerge; Timothy J Davern; Nathan M Bass; Robert K Kerlan; Raphael Merriman; Sandy Feng; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Liver Transpl       Date:  2005-12       Impact factor: 5.799

3.  Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm.

Authors:  Shi-Ming Lin; Chun-Jung Lin; Chen-Chun Lin; Chao-Wei Hsu; Yi-Cheng Chen
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

4.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

5.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Authors:  Kazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

6.  Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

Authors:  M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2008-11-07       Impact factor: 5.315

7.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

8.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

9.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

View more
  66 in total

1.  MR imaging in hepatocellular carcinoma: correlations between MRI features and molecular marker VEGF.

Authors:  Zhaoqin Huang; Xiangjiao Meng; Jianjun Xiu; Xiuqin Xu; Lei Bi; Jie Zhang; Xue Han; Qingwei Liu
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.

Authors:  Naushad Ali; Heba Allam; Randal May; Sripathi M Sureban; Michael S Bronze; Ted Bader; Shahid Umar; Srikant Anant; Courtney W Houchen
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 3.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

4.  Microvascular invasion in hepatocellular carcinoma.

Authors:  Emre Ünal; İlkay Sedakat İdilman; Deniz Akata; Mustafa Nasuh Özmen; Muşturay Karçaaltıncaba
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

5.  Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Authors:  Qian Yu; Chenyu Liu; Rakesh Navuluri; Osman Ahmed
Journal:  Abdom Radiol (NY)       Date:  2021-04-18

6.  Twenty years of Milan criteria: how far do we go.

Authors:  Po-Chih Yang; Nobuhisa Akamatsu; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

7.  Development and preliminary testing of a translational model of hepatocellular carcinoma for MR imaging and interventional oncologic investigations.

Authors:  Scott M Thompson; Matthew R Callstrom; Bruce Knudsen; Jill L Anderson; Rickey E Carter; Joseph P Grande; Lewis R Roberts; David A Woodrum
Journal:  J Vasc Interv Radiol       Date:  2012-01-20       Impact factor: 3.464

8.  Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.

Authors:  Michele Di Martino; Luca Saba; Sandro Bosco; Massimo Rossi; Kirchin A Miles; Rossella Di Miscio; Concetta Valentina Lombardo; Elisabetta Tamponi; Mario Piga; Carlo Catalano
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

9.  Super-stable homogeneous iodinated formulation technology for improving the therapeutic effect of patients with advanced hepatocellular carcinoma.

Authors:  Pan He; Furui Zhong; Bin Luo; Guosong Luo; Xuewen Wang; Xianming Xia; Bo Li
Journal:  Quant Imaging Med Surg       Date:  2020-11

10.  Overexpression of p42.3 promotes cell growth and tumorigenicity in hepatocellular carcinoma.

Authors:  Wei Sun; Wei-Wei Dong; Lin-Lin Mao; Wen-Mei Li; Jian-Tao Cui; Rui Xing; You-Yong Lu
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.